• Voluntarily sign the informed consent and follow the requirements of the protocol.

• No gender limit.

• Age: ≥18 years old and ≤75 years old.

• expected survival time ≥3 months.

• Histologically or cytologically confirmed, unresectable locally advanced or metastatic non-small cell lung cancer.

• Confirmed known HER2-sensitive mutations, investigator-confirmed previous testing results, and trial site laboratory testing results were acceptable.

• Patients in the advanced stage who had received platinum-based chemotherapy and immunotherapy concurrent or sequential therapy were unable to tolerate standard treatment or had disease progression during or after treatment.

• Consent to provide archived tumor tissue or fresh tissue samples from primary or metastatic sites within 2 years for biomarker testing; Participants who were unable to provide tumor tissue samples could be enrolled if they met other inclusion and exclusion criteria after evaluation by investigators.

• Must have at least one measurable lesion according to RECIST v1.1 definition.

⁃ ECOG score 0 or 1.

⁃ Toxicity of previous antineoplastic therapy has returned to grade 1 or less as defined by NCI-CTCAE v5.0 .

⁃ No severe cardiac dysfunction, left ventricular ejection fraction ≥50%.

⁃ Organ function levels must meet the requirements.

⁃ Coagulation function: international normalized ratio (INR) ≤1.5, and activated partial thromboplastin time (APTT) ≤1.5ULN.

⁃ Urine protein ≤2+ or ≤1000mg/24h.

⁃ For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before the start of treatment, serum/urine pregnancy must be negative, and must be non-lactating; All enrolled patients (male or female) were advised to use adequate barrier contraception throughout the treatment cycle and for 6 months after the end of treatment.